Short- and long-term management of peptic ulcer disease: current role of H2-antagonists.
Hepatogastroenterology
; 39 Suppl 1: 47-52, 1992 Feb.
Article
em En
| MEDLINE
| ID: mdl-1349553
ABSTRACT
With numerous active agents available to treat peptic ulcer disease both acutely and long-term, this paper reviews various aspects of these agents and their effect on the disease process, reviewing efficacy, compliance, incidence of relapse, side-effect profile, drug interactions and the effect on the natural history of peptic ulcer disease. Helicobacter pylori is obviously a factor in the occurrence of peptic ulcer disease, but with the high prevalence of asymptomatic infection and evidence suggesting that duodenal ulcer disease may be self-limiting, widespread treatment with bismuth and antibiotics may do more harm than good. Maintenance therapy is recommended for the patient with previous bleeding or other complication, the patient with severe symptoms, and the patient with frequent recurrences. Maintenance therapy appears to reduce the complication rate in the patient with previous bleeding and possibly in the patient with uncomplicated disease, although the incidence of complications in this group is quite low.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Úlcera Péptica
/
Antagonistas dos Receptores H2 da Histamina
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Hepatogastroenterology
Ano de publicação:
1992
Tipo de documento:
Article
País de afiliação:
Geórgia